CERo Therapeutics Holdings, Inc. (CERO)
OTC Markets OTCQB
Price as at 30 Sept 2026, 16:57 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
CERo Therapeutics Holdings, Inc. trades at $0.01. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About CERo Therapeutics Holdings, Inc.
CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its CERO data?
Fundamentals for CERO come from company filings and exchange data, as listed on OTC Markets OTCQB; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 16:57 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for CERO, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.